Saturday, May 25, 2013 Last update: Yesterday, 10:04 PM
Company Tech News as it Breaks
NPS Pharmaceuticals
News articles for NPS Pharmaceuticals:
Wednesday, January 30, 2013
- New Peer-reviewed Publication Offers Guidance for Integrating Gattex® (Teduglutide [rDNA origin]) for Injection into Management of Short Bowel SyndromeThe Journal of Parenteral and Enteral Nutrition recently published clinical considerations and best-practice recommendations for introducing Gattex® (teduglutide [rDNA origin]) for injection ... read more
Friday, December 21, 2012
- FDA Approves Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel SyndromeBEDMINSTER, N.J., Dec. 21, 2012 /PRNewswire/ -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved Gattex(®) (Teduglutide [rDNA origin]) for Injection, for subcutaneous use ... read more